A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses (Q38105238)

28 August 2017

A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses (English)

1 reference

28 August 2017

1 reference

Y Daigo

1

1 reference

28 August 2017

A Takano

2

1 reference

28 August 2017

K Teramoto

3

1 reference

28 August 2017

S Chung

4

1 reference

28 August 2017

Y Nakamura

5

1 reference

28 August 2017

language of work or name

English

0 references

publication date

8 May 2013

1 reference

Clinical Pharmacology & Therapeutics

28 August 2017

1 reference

28 August 2017

94

1 reference

28 August 2017

2

1 reference

28 August 2017

218-223

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2013.90

28 August 2017

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Characterization of a cleavage stimulation factor, 3' pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Critical function for nuclear envelope protein TMEM209 in human pulmonary carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

ADAM8 as a novel serological and histochemical marker for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Transducible peptide therapy for uveal melanoma and retinoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

inferred from DOI database lookup

7 January 2021

based on heuristic

Identification of a novel oncogene, MMS22L, involved in lung and esophageal carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

inferred from DOI database lookup

7 January 2021

based on heuristic

Cancer Tumor antigens

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.90

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2013.90

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference